Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Global health

Antimicrobial resistance is a deadlier threat than cancer, UK chancellor warns

UK chancellor George Osborne

UK chancellor George Osborne warns that antimicrobial resistance will pose “an even greater threat to mankind than cancer” does today unless coordinated global action is taken

Antimicrobial resistance will pose “an even greater threat to mankind than cancer” does today unless coordinated global action is taken, UK chancellor George Osborne has warned.

He addressed delegates at the International Monetary Fund (IMF) in Washington DC on 15 April 2016 to discuss global action to tackle the growing problem of antimicrobial resistance. He said 10 million people could die globally every year by 2050, as a result of antibiotics becoming powerless against common infections — more than currently die from cancer.

This would have an ‘enormous economic cost’, he said, as it is predicted that by 2050, antimicrobial resistance could reduce global GDP by up to 3.5 per cent — a cumulative cost of $100 trillion.

“We have to dramatically shift incentives for pharmaceutical companies and others to create a long-term solution to this problem, with new rewards, funded globally, that support the development of new antibiotics and ensure access to antibiotics in the developing world,” he said.

“To achieve a long-term solution we also need better rapid diagnostics that will cut the vast amounts of unnecessary antibiotic use.”

In 2014, UK prime minister David Cameron commissioned economist Lord O’Neill to lead a Review on Antimicrobial Resistance and look at the increasing global threat it poses and come up with potential solutions.

The review has proposed that the international community create and fund ‘market entry rewards’, large lump sums paid to a pharmaceutical company, or set of companies, that successfully get a new antibiotic or diagnostic to market to move away from the need to recoup development costs through sales. O’Neill and his team will publish their final recommendations in May 2016.

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201017

Readers' comments (2)

  • I think we should train the future prescriber and pharmacist to avoid unnecessary prescription of antibiotics..

    Unsuitable or offensive? Report this comment

  • More culture and sensitivity test should be performed to reduce the use of unwanted antibiotics

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • UK chancellor George Osborne

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.